scope and applicability
Do not transfer immediate-release renal dosing to XR
The XR source does not recommend severe-renal use; the immediate-release source provides a reduced schedule.
What to reconcileConfirm release type before selecting the source. The IR schedule is not an XR workaround.
1 source identities and dates
GlobalRPh RX List - SANCTURA XRGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Trospium extended-release 60 mg capsules, SANCTURA XR; not immediate-release tablets or xanomeline/trospium.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
renal measure and combination
Creatinine transport effects do not rule out acute kidney injury
An isolated creatinine rise can reflect transport effects, but diarrhea-related volume depletion can also cause true injury. The combination-specific severe-renal restriction remains.
What to reconcileAssess the clinical course and alternative filtration markers where appropriate; reconcile companion-drug labels.
2 source identities and dates
GlobalRPh RX List - TUKYSAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.
Read this stored source Pfizer Medical / TUKYSA prescribing informationPfizer Medical / product prescribing information | Source revision: 1/2023
TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.4.
historical source restriction
FDA withdrawal overrides a historical no-adjustment statement
The retained RX renal statement comes from an old UKONIQ label. The separately stored FDA safety communication directs clinicians to stop prescribing after approval withdrawal.
What to reconcileDo not interpret the historical renal statement as current treatment advice. Any exceptional access must be independently established; this tool neither verifies nor authorizes such access.
2 source identities and dates
GlobalRPh RX List - UkoniqGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Withdrawn U.S. approval. Historical oral umbralisib label extract, not current treatment advice.
Read this stored source FDA: UKONIQ approval withdrawal safety communicationU.S. Food and Drug Administration | Source revision: June 1, 2022
U.S. FDA regulatory alert for umbralisib; no current-use endorsement.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.
institution vs primary study
Continuous-HD prophylaxis: institutional interval versus small PK study
UCSF lists prophylaxis every 48 hours during continuous HD. The Jarrell primary abstract studied daily enteral dosing in ten ICU transplant recipients on CVVHD and found that most reached a proposed trough target. These sources differ, but the study is not a comparative clinical-outcomes trial.
What to reconcileReconcile the actual dialysis modality and clearance, absorption, CMV risk, counts and monitoring. Full-text flow-rate details were not reviewed; no universal CRRT dose is derived or automatically preferred.
2 source identities and dates
UCSF: valganciclovir in intermittent and continuous hemodialysisUCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
UCSF adult institutional CMV treatment/prophylaxis; dialysis regimens differ from the product label.
Read this stored source Jarrell et al.: valganciclovir prophylaxis during CVVHD (primary abstract)Jarrell et al. / primary study indexed by PubMed | Source revision: Clinical Infectious Diseases, 2021; published online 2020. PMID 32379860.
Single-center prospective pharmacokinetic study of ten adult solid-organ transplant recipients in ICU on CVVHD; abstract only.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
label vs institution
Adult tablet label versus UCSF intermittent-HD practice
The VALCYTE label provides no adult tablet dose for hemodialysis and says those tablets should not be used. UCSF lists institutional oral treatment and prophylaxis schedules in intermittent HD. This is a real label-versus-institution difference, not two independently agreeing labels.
What to reconcileConfirm CMV indication, transplant context, formulation, dialysis schedule, cytopenias and infectious-disease input. The institutional regimen is not labeled approval; IV ganciclovir is preferred by UCSF for initiation in unstable renal function or dialysis.
2 source identities and dates
VALCYTE: adult renal tablet table and hemodialysis restrictionDailyMed / Genentech | Source revision: December 2025
Adult VALCYTE 450 mg tablets; induction versus maintenance/prevention. Pediatric equations are not substituted.
Read this stored source UCSF: valganciclovir in intermittent and continuous hemodialysisUCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
UCSF adult institutional CMV treatment/prophylaxis; dialysis regimens differ from the product label.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
renal measurement monitoring
Total concentration can mislead when renal protein binding changes
DEPACON describes reduced binding in renal failure, making a total valproate concentration potentially misleading despite its lack of a routine renal reduction. Dialysis PK data do not supply a mandatory supplement.
What to reconcileInterpret the concentration with clinical response, toxicity and binding context. Do not automatically increase dosing to normalize a total concentration or invent a post-HD replacement dose.
1 source identities and dates
GlobalRPh RX List - Valproic Acid (Depacon)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Intravenous valproate sodium; renal pharmacokinetics and concentration interpretation, not a new seizure-treatment schedule.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
historical vs consensus
Historical renal nomogram versus later serious-MRSA exposure monitoring
The 2015 RX label mirror preserves an older steady-state renal nomogram and anuric approach. The 2020 multi-society executive summary favors AUC-guided monitoring for serious invasive MRSA, rather than reliance on trough surrogates or a fixed renal estimate alone.
What to reconcileUse measured exposure, current renal function and the actual dialysis prescription with local monitoring capability. The consensus target is indication-scoped and is not a new fixed dose, oral-vancomycin rule or universal replacement-therapy schedule.
2 source identities and dates
GlobalRPh RX List - Vancomycin Hydrochloride InjectionGlobalRPh-hosted RX List | Source revision: December 2015
Historical December 2015 IV label; not oral vancomycin and not a contemporary stand-alone AUC or dialysis protocol.
Read this stored source ASHP/IDSA/PIDS/SIDP 2020 consensus: serious-MRSA AUC monitoringASHP / IDSA / PIDS / SIDP | Source revision: March 19, 2020; DOI 10.1093/ajhp/zxaa036.
2020 consensus executive summary for serious invasive MRSA infections; not a universal target for all organisms or oral therapy.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
monitoring scope difference
No routine adjustment does not remove oral-vancomycin monitoring
UCSF lists unadjusted oral CDI schedules. FIRVANQ warns of systemic absorption and nephrotoxicity in selected patients, with renal monitoring during and after treatment in older adults.
What to reconcileKeep dose selection separate from absorption/toxicity monitoring; oral treatment is not an IV systemic-infection substitute.
2 source identities and dates
GlobalRPh RX List - FIRVANQGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral vancomycin solution; not an IV systemic-infection regimen.
Read this stored source UCSF oral vancomycin - adult CDI schedulesUCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
Adult oral vancomycin CDI guidance; not treatment for systemic infection.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.1.
qualified no adjustment
Severe-renal use is a benefit-risk qualification, not a calculated dose
The selected source has a studied no-adjustment band and a separate severe-renal/ESRD evidence limitation.
What to reconcileDo not construct a severe-renal dose from hepatic, CYP3A or different-CFTR-product instructions.
1 source identities and dates
GlobalRPh RX List - ALYFTREKGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ALYFTREK oral fixed-combination tablets for its labeled cystic-fibrosis population; not another CFTR-modulator combination.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
monitoring vs dose
No routine renal reduction does not remove tumor-lysis risk
VENCLEXTA retains dosing in its specified renal range but intensifies initiation precautions at a higher kidney-function threshold because renal impairment raises tumor-lysis risk.
What to reconcileReconcile indication-specific ramp-up, tumor burden, prophylaxis, interacting drugs and laboratory setting before starting. Do not use the no-adjustment tag as a green light to bypass tumor-lysis monitoring.
1 source identities and dates
GlobalRPh RX List - Venetoclax (Venclexta)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VENCLEXTA; renal exposure versus tumor-lysis risk at initiation.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
formulation scope
Renal reduction may require a different extended-release presentation
VENBYSI XR adds a renal maximum and strength-delivery limitation to its percentage reductions. EFFEXOR XR and immediate-release venlafaxine have separate local records; a shared ingredient does not make their available strengths or schedules interchangeable.
What to reconcileCalculate the intended clinician-selected dose using the correct product instructions, then verify that the formulation can deliver it. Do not break an extended-release presentation to create an unsupported lower strength.
1 source identities and dates
GlobalRPh RX List - Venlafaxine ER (Venbysi XR)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VENBYSI XR product-specific renal reduction and available-strength limitation.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
renal measurement monitoring
Low muscle mass and assay interference can mislead renal monitoring
The VILTEPSO source cautions that creatinine is unreliable in low-muscle-mass DMD and that excreted drug can interfere with a urine-protein reagent. A low creatinine or positive protein result may need additional interpretation.
What to reconcileFollow the source-specific cystatin-C and urine monitoring plan, specimen timing and assay guidance. Do not turn a potentially misleading estimate into a new dose-reduction algorithm.
1 source identities and dates
GlobalRPh RX List - Viltolarsen (Viltepso)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VILTEPSO for Duchenne muscular dystrophy amenable to exon 53 skipping; kidney monitoring and evidence gap.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
combination indication scope
Co-pack renal restrictions must not inherit single-agent maintenance wording
The RX page includes both H. pylori co-packs and single-agent esophageal indications. Their renal wording differs. This local import is limited to the co-pack table and retains its below-threshold restriction.
What to reconcileIdentify the indication and every component before choosing the table. A single-agent maintenance no-adjustment statement does not authorize either antibiotic co-pack in severe impairment.
1 source identities and dates
GlobalRPh RX List - VoqueznaGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult H. pylori co-packs: TRIPLE contains vonoprazan/amoxicillin/clarithromycin; DUAL omits clarithromycin. Not single-agent maintenance therapy.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
label vs institution
IV vehicle warning versus qualified institutional short-course use
VFEND favors oral therapy below its renal threshold unless an individualized benefit-risk assessment justifies IV use. UCSF acknowledges that warning and discusses limited evidence for short IV courses in selected patients. The guidance differs in emphasis, not through removal of the vehicle warning.
What to reconcileCheck the exact IV product and excipient, oral feasibility, intended duration, creatinine trend, interactions and drug-level monitoring. Neither source supports ignoring renal deterioration or automatically reducing the oral dose.
2 source identities and dates
VFEND IV: SBECD renal restriction and oral-route distinctionDailyMed / Roerig, Pfizer | Source revision: SPL effective March 20, 2026; version 30. Patient information revised January 2026.
VFEND IV, Roerig/Pfizer, SBECD-containing product; adult renal instructions with separate pediatric evidence gap.
Read this stored source UCSF: voriconazole renal dosing and short-course IV caveatUCSF Infectious Diseases Management Program | Source revision: Dosing updated February 2025 as stated on page.
UCSF adult treatment and hematology/BMT prophylaxis; dosing update identified by the page as February 2025.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
regulatory safety update
Withdrawal overrides historical renal prescribing context
The historical OXBRYTA renal subsection remains a source record, but FDA subsequently instructed clinicians to stop prescribing after safety-related withdrawal. This is not a competing renal dose schedule.
What to reconcileDo not use historical renal text to justify new prescribing. Follow the FDA safety communication and clinician-guided transition for existing patients; the tool does not recommend an alternative sickle-cell regimen.
2 source identities and dates
GlobalRPh RX List - Voxelotor (Oxbryta Discontinued)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Historical OXBRYTA source only; FDA withdrawal notice is separately stored and takes priority over historical prescribing context.
Read this stored source FDA: OXBRYTA voluntary withdrawal for safety concernsU.S. Food and Drug Administration | Source revision: September 26, 2024
FDA September 26, 2024 safety communication; historical renal findings do not restore eligibility.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
selected concordance with metric qualification
A fixed-combination renal restriction is not single-agent trospium dosing
The mirror and January 2026 label agree on the selected renal restriction. Both print MDRD-associated eGFR in mL/min without an indexing denominator.
What to reconcileRetain exact printed units, renal wording and the separate urinary-retention contraindication; do not improvise a component-based workaround.
2 source identities and dates
GlobalRPh RX List - COBENFYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.
Read this stored source Xanomeline / trospium - COBENFY oral capsulesDailyMed | Source revision: 1/2026
COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.9.